Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Condition: Prostate CancerIntervention: Drug: lapatinib ditosylateSponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)Completed - verified December 2014
To identify variables that predict persistent hypogonadism and castration in patients with prostate cancer (PCa) treated with brachytherapy (BT).
ABSTRACT Introduction: Tables predicting the probability of a positive bone scan in men with non-metastatic, castrate-resistant prostate cancer have recently been reported. We performed an external validation study of these bone scan positivity tables. Materials and Methods: We performed a retrospective cohort study of patients seen at a tertiary care medical center (1996-2012) to select patients with non-metastatic, castrate-resistant prostate cancer. Abstracted data included demographic, anthropometric, and disease-specific data such as patient race, BMI, PSA kinetics, and primary treatment. Primary outcome was metastasi...
Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and for prostate cancer. Serum concentrations of oestradiol and testosterone are controlled by the hypothalamic-pituitary-gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries, and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration.
Title: Prostate Cancer Treatment: Hormonal TherapyCategory: Diseases and ConditionsCreated: 1/9/2020 12:00:00 AMLast Editorial Review: 1/9/2020 12:00:00 AM
CONCLUSIONS: Developmentally reprogrammed PCa cell models recapitulate features of clinically-advanced prostate tumors including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies PCa cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway. PMID: 31919137 [PubMed - as supplied by publisher]
Conditions: Prostate Cancer; Chemotherapy Effect; Hormone Sensitive Prostate Cancer; Locally Advanced Prostate Carcinoma Interventions: Drug: Neoadjuvant chemotherapy combined with hormone therapy; Drug: Neoadjuvant hormone therapy; Procedure: Radical Prostatectomy (RP)+ extended lymph node dissection Sponsor: RenJi Hospital Not yet recruiting
New England Journal of Medicine,Volume 381, Issue 26, Page 2564-2566, December 2019.
This study is a multicentre, randomised, open-label, phase 3 trial. Patients with localised prostate cancer whose PSA concentrations had decreased to
Conclusions-AEs increase the economic burden and therapy discontinuation among nmPC patients receiving secondary hormonal therapies subsequent to ADTs. These patients should be carefully evaluated for AEs to reduce therapy discontinuation, HCRU, and direct medical costs. PMID: 31835965 [PubMed - as supplied by publisher]